Obesity drug mazdutide reduces weight and waist size in major trial

https://www.news-medical.net/news/20260609/Obesity-drug-mazdutide-reduces-weight-and-waist-size-in-major-trial.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_23_june_2026 A phase 3 trial shows that the dual GLP-1 and glucagon receptor agonist mazdutide drove substantial weight loss and cardiometabolic benefits, while highlighting gastrointestinal side effects that clinicians will need to manage. In a recent JAMA study, researchers reported the outcomes of the Phase 3 GLORY-2 clinical trial. The trial investigated the efficacy of mazdutide (the synthetic peptide analog of the natural mammalian peptide oxyntomodulin) in a cohort of Chinese adults with obesity (BMI ≥ 30 kg/m²) between December 2023 and November 2025.